About Precigen
Precigen is a publicly listed company based in Germantown (United States) founded in 1998 by Thomas David Reed. Gene and cell therapy biopharmaceutical company focused on immuno-oncology, autoimmune, and infectious diseases. Precigen has raised $233.76 million across 4 funding rounds. The company has 143 employees. Precigen has completed 9 acquisitions, including ActoGeniX, EnviroFlight and Exemplar Genetics. Precigen offers products and services including PRGN-2012, Therapeutic Platforms, and Pipeline Therapies. Its focus areas include Diversified Pharmaceuticals, Drugs, Life Sciences and Immunology. Its legal entity is Precigen, Inc. Its competitors include BridgeBio, Spark Therapeutics and Biogen; 3 of its 3 listed competitors have raised funding.
Company details
Precigen was founded in 1998 and is headquartered in Germantown, United States. Operations center on biopharmaceutical development of gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. A preclinical and clinical pipeline is progressed using non-viral and viral expression systems, along with genome editing, DNA and RNA engineering, and protein bioengineering. Precision technologies are applied to achieve on-target delivery and commercialization potential.
- Headquarters Germantown, United States
- Employees 143
- Founders Thomas David Reed
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website precigen.com
- Social LinkedIn X YouTube
- Legal Name Precigen, Inc.
- Annual Revenue$9.68 M (USD)146.73as on Dec 31, 2025
- Net Profit-$250.64 M (USD)-98.55as on Dec 31, 2025
- EBITDA-$103.4 M (USD)-14.66as on Dec 31, 2025
- Total Equity Funding$233.76M (USD)
in 4 rounds
- Latest Funding Round$13M (USD), Post-IPO
Dec 2020
- Employee Count143
- Investments & AcquisitionsActoGeniX
& 8 more
Products & Services of Precigen
Precigen offers a comprehensive portfolio of products and services, including PRGN-2012, Therapeutic Platforms, and Pipeline Therapies.
Gene therapy for treating recurrent respiratory papillomatosis in adults
Systems for gene expression in immuno-oncology applications
Advancing treatments for autoimmune and infectious diseases
Apps and channels of Precigen
its YouTube channel Precigen has 90 subscribers and 7 videos.
Videos from Precigen
The most watched videos on Precigen's YouTube channel, Precigen (90 subscribers). Click a video to play it here.
More on Precigen.
Funding Insights of Precigen
Precigen has successfully raised a total of $233.76M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $13 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $233.76M
- Total Rounds 4
- Last Round Post-IPO — $13M
- First Round $66.94M
(Apr 2011)
All 4 funding rounds of Precigen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $13M | Post-IPO | – | – | – |
| Apr 2012 | $75M | Series D | – | – | – |
| Jun 2011 | $91.83M | Series D | – | – | – |
| Apr 2011 | $66.94M | Series C | – | – | – |
People of Precigen
62 people are tracked at Precigen (33 in leadership, 8 in board & advisors, 21 in team); the tracked headcount is 143.
| Name | Role | Group |
|---|---|---|
Thomas David Reed | Founder | Leadership |
Bryan T. Butman | Senior Vice President And Head Of CMC | Leadership |
Deba Saha | Senior Director, Cell & Gene Therapy, Global Regulatory Affairs -cmc | Leadership |
Roshanak Semnani | Executive Director | Leadership |
Helen Sabzevari | President & CEO | Leadership |
Rob Russell | Vice President Of Human Resources | Leadership |
Douglas E. Brough | SVP & Head of Research | Leadership |
Donald P. Lehr | Chief Legal Officer | Leadership |
Rutul R. Shah | COO | Leadership |
Jeff Cappuccio | Vice President, Sales And Marketing | Leadership |
Woo Joo | Senior Director Biologics | Leadership |
Cory Dauphin | Director Of Clinical Operations | Leadership |
Eric Miracle | Director Of IT OPS | Leadership |
Gregory Potter | Associate Director, Molecular Engineering | Leadership |
Cheryl Bolinger | Sr. Director, Molecular Biology | Leadership |
Harry Thomasian | Chief Financial Officer | Leadership |
Natalia Garcia | Director Of Finance And Accounting | Leadership |
Doug Brough | Senior Vice President & Head Of Research | Leadership |
Phil Tennant | Chief Commercial Officer | Leadership |
Joe Merkert | Vice President, Market Access And Distribution | Leadership |
42 more people are available in the full profile.
Complete people profiles for Precigen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Precigen
Precigen is a publicly listed company on the NASDAQ with ticker symbol PGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Aug 2013
- Listed onNASDAQ: PGEN
- Listed entityPrecigen, Inc.
- Exchange sectorHealth technology
- ISINUS74017N1054
- Share price$7.48 (-2.35% on the day) · 2026-10-13
- Market capitalisation$2.68B
- EPS (diluted, trailing year)$-1.10
- Volume (last session)2,403,748
Financials of Precigen
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $9.7M | -$250.6M | -$103.4M |
| 2024 | $3.9M | -$126.2M | -$90.2M |
| 2023 | $6.2M | -$95.9M | -$82.2M |
| 2022 | $26.9M | -$66.4M | -$67.4M |
| 2021 | $14.3M | -$92.2M | -$83.3M |
Detailed financial statements for Precigen
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Precigen
Precigen has strategically engaged in corporate development activities, having acquired 9 companies. Notable acquisitions include ActoGeniX, EnviroFlight and Exemplar Genetics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Developer of gene-based vaccines for hearing loss and balance disorders | genvec.com | Gaithersburg, United States | 1992 | Jan 2017 | •••• | |
Waste is converted into protein-rich agri feedstock using insects. | enviroflight.net | Yellow Springs, United States | 2009 | Feb 2016 | •••• | |
Genetically modified insects are developed to suppress pest populations. | oxitec.com | Abingdon, United Kingdom | 2002 | Aug 2015 | $160M | |
Nonbrowning apples are developed through genetic modification and breeding. | okspecialtyfruits.com | Summerland, Canada | 1996 | Feb 2015 | •••• | |
Engineering microbes for in situ expression and secretion of novel biotherapeutic proteins and peptides. | actogenix.com | Ghent, Belgium | 2006 | Feb 2015 | $60M | |
Genetic miniature pig models are developed for disease research. | exemplargenetics.com | Sioux Center, United States | 2008 | Jan 2015 | •••• | |
Reproduction and breeding services for livestock genetics are provided. | transova.com | Sioux Center, United States | 1980 | Jul 2014 | •••• | |
Stem-cell-based therapies to stimulate new blood vessel formation | medisteminc.com | San Diego, United States | 2005 | Dec 2013 | $26M | |
Antibody-based therapeutics are developed for biological targets. | immunologix.com | Charleston, United States | 2008 | Oct 2011 | •••• |
Complete acquisition details for Precigen
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Precigen
13 dated milestones of Precigen across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Precigen is founded.
- Funding First funding round of $66.9M.
- Acquisition Acquires Immunologix.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Medistem.
- Acquisition Acquires Trans Ova Genetics.
- Acquisition Acquires Exemplar Genetics.
- Acquisition Acquires ActoGeniX.
- Acquisition Acquires Ok Specialty Fruits.
- Acquisition Acquires Oxitec.
- Acquisition Acquires EnviroFlight.
- Acquisition Acquires Genvec.
- Funding Latest funding round, Post-IPO, of $13.0M.
Competitors of Precigen
Precigen has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Biogen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. |
Detailed competitors of Precigen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Precigen
The website of Precigen (precigen.com) receives about 9.5K visits a month and ranks #2,910,862 among all websites worldwide, #3,892 in Biotechnology and Pharmaceuticals.
- Monthly visits9.5K
▲ 51.3% vs previous month
- Unique visitors2.5K
per month
- Global rank#2,910,862
among all websites
- Category rank#3,892
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.3
- Average visit2 min 15 sec
- DevicesDesktop 35% · Mobile 65%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Precigen (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Precigen
Complete news archive for Precigen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Precigen
Precigen was founded in 1998 and raised its 1st funding round 13 years after it was founded.
Precigen is headquartered in Germantown, United States.
Precigen is a funded company, having raised a total of $233.76M across 4 funding rounds to date. The company's 1st funding round was a Series C of $66.94M, raised on Apr 2011.
Precigen has 143 employees.
Annual revenue of Precigen is $9.68M as on Dec 31, 2025.
Precigen was founded in 1998 and is headquartered in Germantown, United States. Operations center on biopharmaceutical development of gene and cell therapies targeting immuno-oncology, autoimmune disorders, and infectious diseases. A preclinical and clinical pipeline is progressed using non-viral and viral expression systems, along with genome editing, DNA and RNA engineering, and protein bioengineering. Precision technologies are applied to achieve on-target delivery and commercialization potential.
Precigen's top competitors include Spark Therapeutics, BridgeBio and Biogen.
Precigen offers PRGN-2012, Therapeutic Platforms, and Pipeline Therapies.
Yes, Precigen is publicly traded on NASDAQ under the ticker symbol PGEN.
Precigen has made 9 acquisitions, including ActoGeniX, EnviroFlight, and Exemplar Genetics.
Precigen operates through Precigen, Inc..